Drug Trial Radar · NCT02540993
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Jul 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,734
Actual
Start
Sep 17, 2015
Primary completion
Apr 14, 2020
Study completion Apr 14, 2020
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.
Conditions
- Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862)Drug
Oral tablet; starting dose at 10 mg for subjects with an eGFR between 25 to \< 60 mL/min/1.73m² at the Screening Visit; starting dose at 20 mg for subjects with an eGFR ≥ 60 mL/min/1.73m² at the Screening Visit; dose could be up-titrated from Month 1 onwards or down-titrated at any time during the study; once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
PlaceboDrug
Matching placebo, oral tablet, once daily in the morning, until the trial was completed provided there were no safety grounds for discontinuing treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal DeathTime frame: From randomization up until the first occurrence of the primary renal composite endpoint, or censoring at the end of the study, with an average follow-up time of 32 months
Locations
978 sites in 48 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Fort Payne, Alabama
Site not named
Huntsville, Alabama
Site not named
Mesa, Arizona
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Prescott, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Arvin, California
Site not named
Chula Vista, California
Site not named
Dublin, California
Site not named
El Centro, California
Site not named
Fresno, California
Site not named
Fresno, California
Site not named
La Mesa, California
Site not named
Loma Linda, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Northridge, California
Site not named
Port Hueneme, California
Site not named
Poway, California
Site not named
Rancho Cucamonga, California
Site not named
Rialto, California
Site not named
Roseville, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Torrance, California
Site not named
New Haven, Connecticut
Site not named
Waterbury, Connecticut
Site not named
Fleming Island, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Gainesville, Florida
Site not named
Hialeah, Florida
Site not named
Hialeah, Florida
Site not named
Hollywood, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Showing 40 of 978 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.